§ 379dd. Establishment and functions of the Foundation
3,106 words·~14 min read·
/usc/title-21/section-379ddA research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)In general A nonprofit corporation to be known as the Reagan-Udall Foundation for the Food and Drug Administration (referred to in this part as the “Foundation”) shall be established in accordance with this section. The Foundation shall be headed by an Executive Director, appointed by the members of the Board of Directors under subsection (e).1 The Foundation shall not be an agency or instrumentality of the United States Government.
(b)Purpose of Foundation The purpose of the Foundation is to advance the mission of the Food and Drug Administration to modernize medical, veterinary, food, food ingredient, and cosmetic product development, accelerate innovation, and enhance product safety.
(c)Duties of the Foundation The Foundation shall—
(1)taking into consideration the Critical Path reports and priorities published by the Food and Drug Administration, identify unmet needs in the development, manufacture, and evaluation of the safety and effectiveness, including postapproval, of devices, including diagnostics, biologics, and drugs, and the safety of food, food ingredients, and cosmetics, and including the incorporation of more sensitive and predictive tools and devices to measure safety;
(2)establish goals and priorities in order to meet the unmet needs identified in paragraph (1);
(3)in consultation with the Secretary, identify existing and proposed Federal intramural and extramural research and development programs relating to the goals and priorities established under paragraph (2), coordinate Foundation activities with such programs, and minimize Foundation duplication of existing efforts;
(4)award grants to, or enter into contracts, memoranda of understanding, or cooperative agreements with, scientists and entities, which may include the Food and Drug Administration, university consortia, public-private partnerships, institutions of higher education, entities described in section 501(c)(3) of title 26 (and exempt from tax under section 501(a) of such title), and industry, to efficiently and effectively advance the goals and priorities established under paragraph (2);
(5)recruit meeting participants and hold or sponsor (in whole or in part) meetings as appropriate to further the goals and priorities established under paragraph (2);
(6)release and publish information and data and, to the extent practicable, license, distribute, and release material, reagents, and techniques to maximize, promote, and coordinate the availability of such material, reagents, and techniques for use by the Food and Drug Administration, nonprofit organizations, and academic and industrial researchers to further the goals and priorities established under paragraph (2);
(7)ensure that—
(A)action is taken as necessary to obtain patents for inventions developed by the Foundation or with funds from the Foundation;
(B)action is taken as necessary to enable the licensing of inventions developed by the Foundation or with funds from the Foundation; and
(C)executed licenses, memoranda of understanding, material transfer agreements, contracts, and other such instruments, promote, to the maximum extent practicable, the broadest conversion to commercial and noncommercial applications of licensed and patented inventions of the Foundation to further the goals and priorities established under paragraph (2);
(8)provide objective clinical and scientific information to the Food and Drug Administration and, upon request, to other Federal agencies to assist in agency determinations of how to ensure that regulatory policy accommodates scientific advances and meets the agency’s public health mission;
(9)conduct annual assessments of the unmet needs identified in paragraph (1); and
(10)carry out such other activities consistent with the purposes of the Foundation as the Board determines appropriate.
(d)Board of Directors
(1)Establishment
(A)In general The Foundation shall have a Board of Directors (referred to in this part as the “Board”), which shall be composed of ex officio and appointed members in accordance with this subsection. All appointed members of the Board shall be voting members.
(B)Ex officio members The ex officio members of the Board shall be the following individuals or their designees:
(i)The Commissioner.
(ii)The Director of the National Institutes of Health.
(iii)The Director of the Centers for Disease Control and Prevention.
(iv)The Director of the Agency for Healthcare Research and Quality.
(C)Appointed members
(i)In general The ex officio members of the Board under subparagraph
(B)shall, by majority vote, appoint to the Board 14 individuals, of which 9 shall be from a list of candidates to be provided by the National Academy of Sciences and 5 shall be from lists of candidates provided by patient and consumer advocacy groups, professional scientific and medical societies, and industry trade organizations. Of such appointed members—
(I)4 shall be representatives of the general pharmaceutical, device, food, cosmetic, and biotechnology industries;
(II)3 shall be representatives of academic research organizations;
(III)2 shall be representatives of patient or consumer advocacy organizations;
(IV)1 shall be a representative of health care providers; and
(V)4 shall be at-large members with expertise or experience relevant to the purpose of the Foundation.
(ii)Additional members The Board, through amendments to the bylaws of the Foundation, may provide that the number of voting members of the Board shall be a number (to be specified in such amendment) greater than 14. Any Board positions that are established by any such amendment shall be appointed (by majority vote) by the individuals who, as of the date of such amendment, are voting members of the Board and persons so appointed may represent any of the categories specified in subclauses
(I)through
(V)of clause (i), so long as no more than 30 percent of the total voting members of the Board (including members whose positions are established by such amendment) are representatives of the general pharmaceutical, device, food, cosmetic, and biotechnology industries.
(iii)Requirements
(I)Expertise The ex officio members, acting pursuant to clause (i), and the Board, acting pursuant to clause (ii), shall ensure the Board membership includes individuals with expertise in areas including the sciences of developing, manufacturing, and evaluating the safety and effectiveness of devices, including diagnostics, biologics, and drugs, and the safety of food, food ingredients, and cosmetics.
(II)Federal employees No employee of the Federal Government shall be appointed as a member of the Board under this subparagraph or under paragraph (3)(B). For purposes of this section, the term “employee of the Federal Government” does not include a special Government employee, as that term is defined in section 202(a) of title 18.
(D)Initial meeting
(i)In general Not later than 30 days after September 27, 2007, the Secretary shall convene a meeting of the ex officio members of the Board to—
(I)incorporate the Foundation; and
(II)appoint the members of the Board in accordance with subparagraph (C).
(ii)Service of ex officio members Upon the appointment of the members of the Board under clause (i)(II)—
(I)the terms of service of the Director of the Centers for Disease Control and Prevention and of the Director of the Agency for Healthcare Research and Quality as ex officio members of the Board shall terminate; and
(II)the Commissioner and the Director of the National Institutes of Health shall continue to serve as ex officio members of the Board, but shall be nonvoting members.
(iii)Chair The ex officio members of the Board under subparagraph
(B)shall designate an appointed member of the Board to serve as the Chair of the Board.
(2)Duties of Board The Board shall—
(A)establish bylaws for the Foundation that—
(i)are published in the Federal Register and available for public comment;
(ii)establish policies for the selection of the officers, employees, agents, and contractors of the Foundation;
(iii)establish policies, including ethical standards, for the acceptance, solicitation, and disposition of donations and grants to the Foundation and for the disposition of the assets of the Foundation, including appropriate limits on the ability of donors to designate, by stipulation or restriction, the use or recipient of donated funds;
(iv)establish policies that would subject all employees, fellows, and trainees of the Foundation to the conflict of interest standards under section 208 of title 18;
(v)establish licensing, distribution, and publication policies that support the widest and least restrictive use by the public of information and inventions developed by the Foundation or with Foundation funds to carry out the duties described in paragraphs
(6)and
(7)of subsection (c), and may include charging cost-based fees for published material produced by the Foundation;
(vi)specify principles for the review of proposals and awarding of grants and contracts that include peer review and that are consistent with those of the Foundation for the National Institutes of Health, to the extent determined practicable and appropriate by the Board;
(vii)specify a cap on administrative expenses for recipients of a grant, contract, or cooperative agreement from the Foundation;
(viii)establish policies for the execution of memoranda of understanding and cooperative agreements between the Foundation and other entities, including the Food and Drug Administration;
(ix)establish policies for funding training fellowships, whether at the Foundation, academic or scientific institutions, or the Food and Drug Administration, for scientists, doctors, and other professionals who are not employees of regulated industry, to foster greater understanding of and expertise in new scientific tools, diagnostics, manufacturing techniques, and potential barriers to translating basic research into clinical and regulatory practice;
(x)specify a process for annual Board review of the operations of the Foundation; and
(xi)establish specific duties of the Executive Director;
(B)prioritize and provide overall direction to the activities of the Foundation;
(C)evaluate the performance of the Executive Director; and
(D)carry out any other necessary activities regarding the functioning of the Foundation.
(3)Terms and vacancies
(A)Term The term of office of each member of the Board appointed under paragraph (1)(C)(i), and the term of office of any member of the Board whose position is established pursuant to paragraph (1)(C)(ii), shall be 4 years, except that—
(i)the terms of offices for the members of the Board initially appointed under paragraph (1)(C)(i) shall expire on a staggered basis as determined by the ex officio members; and
(ii)the terms of office for the persons initially appointed to positions established pursuant to paragraph (1)(C)(ii) may be made to expire on a staggered basis, as determined by the individuals who, as of the date of the amendment establishing such positions, are members of the Board.
(B)Vacancy Any vacancy in the membership of the Board—
(i)shall not affect the power of the remaining members to execute the duties of the Board; and
(ii)shall be filled by appointment by the appointed members described in paragraph (1)(C) by majority vote.
(C)Partial term If a member of the Board does not serve the full term applicable under subparagraph (A), the individual appointed under subparagraph
(B)to fill the resulting vacancy shall be appointed for the remainder of the term of the predecessor of the individual.
(D)Serving past term A member of the Board may continue to serve after the expiration of the term of the member until a successor is appointed.
(4)Compensation Members of the Board may not receive compensation for service on the Board. Such members may be reimbursed for travel, subsistence, and other necessary expenses incurred in carrying out the duties of the Board, as set forth in the bylaws issued by the Board.
(e)Incorporation The ex officio members of the Board shall serve as incorporators and shall take whatever actions necessary to incorporate the Foundation.
(f)Nonprofit status In carrying out subsection (b), the Board shall establish such policies and bylaws under subsection (d), and the Executive Director shall carry out such activities under subsection (g), as may be necessary to ensure that the Foundation maintains status as an organization that—
(1)is described in subsection (c)(3) of section 501 of title 26; and
(2)is, under subsection
(a)of such section, exempt from taxation.
(g)Executive Director
(1)In general The Board shall appoint an Executive Director who shall serve at the pleasure of the Board. The Executive Director shall be responsible for the day-to-day operations of the Foundation and shall have such specific duties and responsibilities as the Board shall prescribe.
(2)Compensation The compensation of the Executive Director shall be fixed by the Board.
(h)Administrative powers In carrying out this part, the Board, acting through the Executive Director, may—
(1)adopt, alter, and use a corporate seal, which shall be judicially noticed;
(2)hire, promote, compensate, and discharge 1 or more officers, employees, and agents, as may be necessary, and define their duties;
(3)prescribe the manner in which—
(A)real or personal property of the Foundation is acquired, held, and transferred;
(B)general operations of the Foundation are to be conducted; and
(C)the privileges granted to the Board by law are exercised and enjoyed;
(4)with the consent of the applicable executive department or independent agency, use the information, services, and facilities of such department or agencies in carrying out this section;
(5)enter into contracts with public and private organizations for the writing, editing, printing, and publishing of books and other material;
(6)hold, administer, invest, and spend any gift, devise, or bequest of real or personal property made to the Foundation under subsection (i);
(7)enter into such other contracts, leases, cooperative agreements, and other transactions as the Board considers appropriate to conduct the activities of the Foundation;
(8)modify or consent to the modification of any contract or agreement to which it is a party or in which it has an interest under this part;
(9)take such action as may be necessary to obtain patents and licenses for devices and procedures developed by the Foundation and its employees;
(10)sue and be sued in its corporate name, and complain and defend in courts of competent jurisdiction;
(11)appoint other groups of advisors as may be determined necessary to carry out the functions of the Foundation; and
(12)exercise other powers as set forth in this section, and such other incidental powers as are necessary to carry out its powers, duties, and functions in accordance with this part.
(i)Acceptance of funds from other sources The Executive Director may solicit and accept on behalf of the Foundation, any funds, gifts, grants, devises, or bequests of real or personal property made to the Foundation, including from private entities, for the purposes of carrying out the duties of the Foundation.
(j)Service of Federal employees Federal Government employees may serve on committees advisory to the Foundation and otherwise cooperate with and assist the Foundation in carrying out its functions, so long as such employees do not direct or control Foundation activities.
(k)Detail of Government employees; fellowships
(1)Detail from Federal agencies Federal Government employees may be detailed from Federal agencies with or without reimbursement to those agencies to the Foundation at any time, and such detail shall be without interruption or loss of civil service status or privilege. Each such employee shall abide by the statutory, regulatory, ethical, and procedural standards applicable to the employees of the agency from which such employee is detailed and those of the Foundation.
(2)Voluntary service; acceptance of Federal employees
(A)Foundation The Executive Director of the Foundation may accept the services of employees detailed from Federal agencies with or without reimbursement to those agencies.
(B)Food and Drug Administration The Commissioner may accept the uncompensated services of Foundation fellows or trainees. Such services shall be considered to be undertaking an activity under contract with the Secretary as described in section 379 of this title.
(l)Annual reports
(1)Reports to Foundation Any recipient of a grant, contract, fellowship, memorandum of understanding, or cooperative agreement from the Foundation under this section shall submit to the Foundation a report on an annual basis for the duration of such grant, contract, fellowship, memorandum of understanding, or cooperative agreement, that describes the activities carried out under such grant, contract, fellowship, memorandum of understanding, or cooperative agreement.
(2)Report to Congress and the FDA Beginning with fiscal year 2009, the Executive Director shall submit to Congress and the Commissioner an annual report that—
(A)describes the activities of the Foundation and the progress of the Foundation in furthering the goals and priorities established under subsection (c)(2), including the practical impact of the Foundation on regulated product development;
(B)provides a specific accounting of the source and use of all funds used by the Foundation to carry out such activities; and
(C)provides information on how the results of Foundation activities could be incorporated into the regulatory and product review activities of the Food and Drug Administration.
(m)Separation of funds The Executive Director shall ensure that the funds received from the Treasury are managed as individual programmatic funds under subsection (i), according to best accounting practices.
(n)Funding From amounts appropriated to the Food and Drug Administration for each fiscal year, the Commissioner shall transfer not less than $1,250,000 and not more than $5,000,000, to the Foundation to carry out subsections (a), (b), and
(d)through (m).
(June 25, 1938, ch. 675, § 770, as added Pub. L. 110–85, title VI, § 601(a), Sept. 27, 2007, 121 Stat. 890; amended Pub. L. 114–255, div. A, title III, § 3076, Dec. 13, 2016, 130 Stat. 1139; Pub. L. 117–101, § 2(a), Mar. 15, 2022, 136 Stat. 47.)
Connections112 cite this · traces to 6
Cited by 112 sections · top 60
public-private-law
- Public Law 116-260Consolidated Appropriations Act, 2021
- Public Law 115-141Consolidated Appropriations Act, 2018
- Public Law 117-328Consolidated Appropriations Act, 2023
- Public Law 114-113Consolidated Appropriations Act, 2016
- Public Law 116-94Further Consolidated Appropriations Act, 2020
- Public Law 113-235Consolidated and Further Continuing Appropriations Act, 2015
- Public Law 113-76Consolidated Appropriations Act, 2014
- Public Law 115-31Consolidated Appropriations Act, 2017
- Public Law 117-103Consolidated Appropriations Act, 2022
- Public Law 114-25521st Century Cures Act
- Public Law 113-6Consolidated and Further Continuing Appropriations Act, 2013
- Public Law 116-6Consolidated Appropriations Act, 2019
- Public Law 119-37Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
- Public Law 117-101Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
U.S. Code
statutes-at-large
- Public LawMaking appropriations for the fiscal year ending September 30, 2017, and for other purposes
- Public Law 113–6Making consolidated appropriations and further continuing appropriations for the fiscal year ending September 30, 2013, and for other purposes
- Public Law 110–85To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes
- Public Law 115–141To amend the State Department Basic Authorities Act of 1956 to include severe forms of trafficking in persons within the definition of transnational organized crime for purposes of the rewards program of the Department of State, and for other purposes
- Public Law 114–113Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2016, and for other purposes
- Public Law 116–6
- Public Law 117–103Making consolidated appropriations for the fiscal year ending September 30, 2022, and for providing emergency assistance for the situation in Ukraine, and for other purposes
- Public Law 116–260Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes
- Public Law 111–80Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2010, and for other purposes
- Public Law 114–255To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes
- Public Law 110–161Making appropriations for the Department of State, foreign operations, and related programs for the fiscal year ending September 30, 2008, and for other purposes
- Public Law 116–94Making further consolidated appropriations for the fiscal year ending September 30, 2020, and for other purposes
- Public Law 117–328Making consolidated appropriations for the fiscal year ending September 30, 2023, and for providing emergency assistance for the situation in Ukraine, and for other purposes
- Public Law 111–8Making omnibus appropriations for the fiscal year ending September 30, 2009, and for other purposes
- Public Law 117–101To increase funding for the Reagan-Udall Foundation for the Food and Drug Administration and for the Foundation for the National Institutes of Health
statute-compilations
- Sec. 1269Notwithstanding section 1101, the level for “Related Agencies and Food and Drug Administration, Food and Drug Administration, Salaries and Expenses” shall be $3,655,687,000: *Provided*, That of the amount provided under this heading, $667,057,000 shall be derived from prescription drug user fees authorized by section 736 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h), shall be credited to this account and remain available until expended, and shall not include any fees pursuant to paragraphs (2) and (3) of section 736(a) of such Act (21 U.S.C. 379h(a)(2) and (a)(3)) assessed for fiscal year 2012 but collected in fiscal year 2011; $61,860,000 shall be derived from medical device user fees authorized by section 738 of such Act (21 U.S.C. 379j), and shall be credited to this account and remain available until expended; $19,448,000 shall be derived from animal drug user fees authorized by section 740 of such Act (21 U.S.C. 379j-12), and shall be credited to this account and remain available until expended; $5,397,000 shall be derived from animal generic drug user fees authorized by section 741 of such Act (21 U.S.C. 379f), and shall be credited to this account and shall remain available until expended; and $450,000,000 shall be derived from tobacco product user fees authorized by section 919 of such Act (21 U.S.C. 387s) and shall be credited to this account and remain available until expended: *Provided** further*, That in addition and notwithstanding any other provision under this heading, amounts collected for prescription drug user fees that exceed the fiscal year 2011 limitation are appropriated and shall be credited to this account and remain available until expended: *Provided further*, That fees derived from prescription drug, medical device, animal drug, animal generic drug, and tobacco product assessments for fiscal year 2011 received during fiscal year 2011, including any such fees assessed prior to fiscal year 2011 but credited for fiscal year 2011, shall be subject to the fiscal year 2011 limitations: *Provided further,* That none of these funds shall be used to develop, establish, or operate any program of user fees authorized by 31 U.S.C. 9701: *Provided further*, That of the total amount appropriated under this heading: (1) $837,358,000 shall be for the Center for Food Safety and Applied Nutrition and related field activities in the Office of Regulatory Affairs; (2) $957,116,000 shall be for the Center for Drug Evaluation and Research and related field activities in the Office of Regulatory Affairs; (3) $325,647,000 shall be for the Center for Biologics Evaluation and Research and for related field activities in the Office of Regulatory Affairs; (4) $161,730,000 shall be for the Center for Veterinary Medicine and for related field activities in the Office of Regulatory Affairs; (5) $359,781,000 shall be for the Center for Devices and Radiological Health and for related field activities in the Office of Regulatory Affairs; (6) $60,664,000 shall be for the National Center for Toxicological Research; (7) $421,463,000 shall be for the Center for Tobacco Products and for related field activities in the Office of Regulatory Affairs; (8) not to exceed $136,239,000 shall be for Rent and Related activities, of which $41,951,000 is for White Oak Consolidation, other than the amounts paid to the General Services Administration for rent; (9) not to exceed $183,048,000 shall be for payments to the General Services Administration for rent; and (10) $212,642,000 shall be for other activities, including the Office of the Commissioner of Food and Drugs; the Office of Foods; the Office of the Chief Scientist; the Office of Policy, Planning and Budget; the Office of International Programs; the Office of Administration; and central services for these offices: *Provided further,* That none of the funds made available under this heading shall be used to transfer funds under section 770(n) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd): *Provided further*, That not to exceed $25,000 of the amount provided under this heading shall be for official reception and representation expenses, not otherwise provided for, as determined by the Commissioner: *Provided further,* That funds may be transferred from one specified activity to another with the prior approval of the Committees on Appropriations of both Houses of Congress.
- Sec. 163Section 4144(d) of the Motor Carrier Safety Reauthorization Act of 2005 (49 U.S.C. 31100 note) shall be applied by substituting the date specified in section 106(3) of this Act for “September 30, 2025”.
- Sec. 6ADJUSTMENTS TO COMPENSATION
- Sec. 9OFFICE OF MANAGEMENT AND BUDGET REPORTING REQUIREMENT
- Sec. 8LAUNCH LIABILITY EXTENSION
- Sec. 5AVAILABILITY OF FUNDS
- Sec. 8CORRECTION
- Sec. 9ADJUSTMENTS TO COMPENSATION
- Sec. 7ADJUSTMENTS TO COMPENSATION
- Sec. 413None of the funds made available by this Act may be used by the Secretary of Veterans Affairs under section 5502 of title 38, United States Code, in any case arising out of the administration by the Secretary of laws and benefits under such title, to report a person who is deemed mentally incapacitated, mentally incompetent, or to be experiencing an extended loss of consciousness as a person who has been adjudicated as a mental defective under subsection (d)(4) or (g)(4) of section 922 of title 18, United States Code, without the order or finding of a judge, magistrate, or other judicial authority of competent jurisdiction that such person is a danger to himself or herself or others.
- Sec. 530Of amounts deposited in the Child Enrollment Contingency Fund prior to the beginning of fiscal year 2020 under section 2104(n)(2) of the Social Security Act and the income derived from investment of those funds pursuant to section 2104(n)(2)(C) of that Act, $6,093,181,000 shall not be available for obligation in this fiscal year.
- Sec. 3076REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION
- Sec. 541### (a)
- Sec. 11PAYMENTS IN LIEU OF TAXES
register
bill
- Sec. 1Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 2283Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 2283Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 2283Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 2283Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 3076Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 6Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 6Reagan-Udall Foundation for the Food and Drug Administration
- Sec. 1011Reagan-Udall Foundation and Foundation for the National Institutes of Health
- Sec. 110Reagan-Udall Foundation and Foundation for the National Institutes of Health
- Sec. 2Reagan-Udall Foundation and Foundation for the National Institutes of Health
- Sec. 2Reagan-Udall Foundation and Foundation for the National Institutes of Health
- Sec. 2Reagan-Udall Foundation and Foundation for the National Institutes of Health
- Sec. 2Reagan-Udall Foundation and Foundation for the National Institutes of Health
Traces to 6 documents
U.S. Code
6 references not yet in our index
- 1
- June 25, 1938, ch. 675, § 770
- Pub. L. 110–85, title VI, § 601(a)
- 121 Stat. 890
- 130 Stat. 1139
- 136 Stat. 47
Citation graph
cites case law
§ 379dd
Establishment and functions of the Foundation
Bills×53
Stat.×19
Pub. L.×18
Stat. Comp.×18
U.S.C.×3
Fed. Reg.×1
Cite1
ActJune 25, 1938, ch. 675, § 770
Pub. L.Pub. L. 110–85, title VI, § 601(a)
Stat.121 Stat. 890
Stat.130 Stat. 1139
Cites 12 · showing 11Cited by 112 across 6 sources